Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more
Actinogen Medical Limited (ATGGF) - Total Assets
Latest total assets as of June 2025: $24.48 Million USD
Based on the latest financial reports, Actinogen Medical Limited (ATGGF) holds total assets worth $24.48 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Actinogen Medical Limited - Total Assets Trend (2008–2025)
This chart illustrates how Actinogen Medical Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Actinogen Medical Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Actinogen Medical Limited's total assets of $24.48 Million consist of 91.6% current assets and 8.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 67.4% |
| Accounts Receivable | $5.80 Million | 23.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.78 Million | 7.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Actinogen Medical Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Actinogen Medical Limited's current assets represent 91.6% of total assets in 2025, an increase from 88.3% in 2008.
- Cash Position: Cash and equivalents constituted 67.4% of total assets in 2025, down from 86.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 23.7% of total assets.
Actinogen Medical Limited Competitors by Total Assets
Key competitors of Actinogen Medical Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Actinogen Medical Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Actinogen Medical Limited generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Actinogen Medical Limited is currently not profitable relative to its asset base.
Actinogen Medical Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.76 | 13.91 | 10.98 |
| Quick Ratio | 3.76 | 14.21 | 10.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.47 Million | $ 17.52 Million | $ 7.42 Million |
Actinogen Medical Limited - Advanced Valuation Insights
This section examines the relationship between Actinogen Medical Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.29 |
| Latest Market Cap to Assets Ratio | 2.58 |
| Asset Growth Rate (YoY) | 14.9% |
| Total Assets | $24.48 Million |
| Market Capitalization | $63.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Actinogen Medical Limited's assets at a significant premium ( 2.58x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Actinogen Medical Limited's assets grew by 14.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Actinogen Medical Limited (2008–2025)
The table below shows the annual total assets of Actinogen Medical Limited from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $24.48 Million | +14.87% |
| 2024-06-30 | $21.31 Million | +40.13% |
| 2023-06-30 | $15.21 Million | -34.74% |
| 2022-06-30 | $23.31 Million | +26.81% |
| 2021-06-30 | $18.38 Million | +53.97% |
| 2020-06-30 | $11.94 Million | -26.42% |
| 2019-06-30 | $16.22 Million | -10.01% |
| 2018-06-30 | $18.03 Million | +76.55% |
| 2017-06-30 | $10.21 Million | -21.16% |
| 2016-06-30 | $12.95 Million | -16.88% |
| 2015-06-30 | $15.58 Million | +1134.74% |
| 2014-06-30 | $1.26 Million | +357.70% |
| 2013-06-30 | $275.67K | -40.82% |
| 2012-06-30 | $465.80K | -59.17% |
| 2011-06-30 | $1.14 Million | -14.98% |
| 2010-06-30 | $1.34 Million | -33.16% |
| 2009-06-30 | $2.01 Million | -31.75% |
| 2008-06-30 | $2.94 Million | -- |